Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 11:9:811917.
doi: 10.3389/fbioe.2021.811917. eCollection 2021.

Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders

Affiliations
Review

Nanomedicine of Plant Origin for the Treatment of Metabolic Disorders

Fang Hu et al. Front Bioeng Biotechnol. .

Abstract

Metabolic disorders are major clinical challenges of health that are progressing globally. A concurrence of metabolic disorders such as obesity, insulin resistance, atherogenic dyslipidemia, and systematic hypertension leads to metabolic syndrome. Over the past years, the metabolic syndrome leads to a five- and two-fold rise in diabetes mellitus type II and cardiovascular diseases. Natural products specifically plant extracts have insulin-sensitizing, anti-inflammatory, and antioxidant properties and are also considered as an alternative option due to few adverse effects. Nanotechnology is one of the promising strategies, which improves the effectiveness of treatment and limits side effects. This review mainly focuses on plant extract-based nanosystems in the management of the metabolic syndrome. Numerous nano-drug delivery systems, i.e., liposomes, hydrogel nanocomposites, nanoemulsions, micelles, solid lipid, and core-shell nanoparticles, have been designed using plant extracts. It has been found that most of the nano-formulations successfully reduced oxidative stress, insulin resistance, chronic inflammation, and lipid profile in in vitro and in vivo studies as plant extracts interfere with the pathways of metabolic syndrome. Thus, these novel plant-based nanosystems could act as a promising candidate for clinical applications.

Keywords: medicinal plants; metabolic disorders; nano drug; nano system; phytochemicals.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Overview of metabolic syndrome.
FIGURE 2
FIGURE 2
Structure of non-flavinoid (A) and flavinoid (B).
FIGURE 3
FIGURE 3
Importance of plant-extract-encapsulated nanosystems for metabolic disorders.

Similar articles

Cited by

References

    1. Abu-Taweel G. M., Attia M. F., Hussein J., Mekawi E. M., Galal H. M., Ahmed E. I., et al. (2020). Curcumin Nanoparticles Have Potential Antioxidant Effect and Restore Tetrahydrobiopterin Levels in Experimental Diabetes. Biomed. Pharmacother. 131, 110688. 10.1016/J.BIOPHA.2020.110688 - DOI - PubMed
    1. Ahangarpour A., Oroojan A. A., Khorsandi L., Kouchak M., Badavi M. (2019). Antioxidant, Anti-apoptotic, and Protective Effects of Myricitrin and its Solid Lipid Nanoparticle on Streptozotocin-Nicotinamide-Induced Diabetic Nephropathy in Type 2 Diabetic Male Mice. Iran. J. Basic Med. Sci. 22 (12), 1424–1431. 10.22038/IJBMS.2019.13989 - DOI - PMC - PubMed
    1. Ahangarpour A., Oroojan A. A., Khorsandi L., Kouchak M., Badavi M. (2018). Solid Lipid Nanoparticles of Myricitrin Have Antioxidant and Antidiabetic Effects on Streptozotocin-Nicotinamide-Induced Diabetic Model and Myotube Cell of Male Mouse. Oxidative Med. Cell Longevity 2018, 1–18. 10.1155/2018/7496936 - DOI - PMC - PubMed
    1. Al-Kurdy M. J., Khadim Khudair K. (2020). The Effect of Black Currant Selenium Nanoparticles on Dyslipidemia and Oxidant-Antioxidant Status in D-Galactose Treated Rats. Kufa J. Vet. Med. Sci. 11, 23–38. http://journals.uokufa.edu.iq/index.php/kjvs/article/view/9357
    1. Alam T., Khan S., Gaba B., Haider M. F., Baboota S., Ali J. (2017). Nanocarriers as Treatment Modalities for Hypertension. Drug Deliv. 24 (1), 358–369. 10.1080/10717544.2016.1255999 - DOI - PMC - PubMed